{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:40:38Z","timestamp":1787002838763,"version":"build-2736575974"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"18","license":[{"start":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:00:00Z","timestamp":1726012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:00:00Z","timestamp":1726012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1038\/s41433-024-03327-3","type":"journal-article","created":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T12:03:07Z","timestamp":1726056187000},"page":"3473-3480","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Two-year efficacy and safety of different anti-vascular endothelial growth factor regimens for neovascular age-related macular degeneration: a network meta-analysis of randomized controlled trials"],"prefix":"10.1038","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9015-0480","authenticated-orcid":false,"given":"Hong","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengjiao","family":"Bu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu","family":"Xin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5689-9989","authenticated-orcid":false,"given":"Jingchao","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4185-7732","authenticated-orcid":false,"given":"Taomin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,11]]},"reference":[{"key":"3327_CR1","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/S0140-6736(22)02609-5","volume":"401","author":"R Guymer","year":"2023","unstructured":"Guymer R, Campbell T. Age-related macular degeneration. Lancet. 2023;401:1459\u201372.","journal-title":"Lancet"},{"key":"3327_CR2","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.gendis.2021.02.009","volume":"9","author":"Y Deng","year":"2022","unstructured":"Deng Y, Qiao L, Du M, Qu C, Wan L, Li J, et al. Age-related macular degeneration: epidemiology, genetics, pathophysiology, diagnosis, and targeted therapy. Genes Dis. 2022;9:62\u201379.","journal-title":"Genes Dis"},{"key":"3327_CR3","doi-asserted-by":"publisher","first-page":"ORSF5","DOI":"10.1167\/iovs.13-12789","volume":"54","author":"R Klein","year":"2013","unstructured":"Klein R, Klein BE. The prevalence of age-related eye diseases and visual impairment in aging: current estimates. Invest Ophthalmol Vis Sci. 2013;54:ORSF5\u2013ORSF13.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3327_CR4","unstructured":"American Academy of Ophthalmology Retina\/Vitreous Panel. Preferred Practice Pattern Guidelines. Age-related macular degeneration. San Francisco, CA: American Academy of Ophthalmology; 2015."},{"key":"3327_CR5","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1001\/archophthalmol.2010.318","volume":"129","author":"R Klein","year":"2011","unstructured":"Klein R, Chou CF, Klein BE, Zhang X, Meuer SM, Saaddine JB. Prevalence of age-related macular degeneration in the US population. Arch Ophthalmol. 2011;129:75\u201380.","journal-title":"Arch Ophthalmol"},{"key":"3327_CR6","doi-asserted-by":"publisher","first-page":"943915","DOI":"10.3389\/fbioe.2022.943915","volume":"10","author":"D Song","year":"2022","unstructured":"Song D, Liu P, Shang K, Ma Y. Application and mechanism of anti-VEGF drugs in age-related macular degeneration. Front Bioeng Biotech. 2022;10:943915.","journal-title":"Front Bioeng Biotech"},{"key":"3327_CR7","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1517\/13543770902762885","volume":"20","author":"A Ozkiris","year":"2010","unstructured":"Ozkiris A. Anti-VEGF agents for age-related macular degeneration. Expert Opin Ther Pat. 2010;20:103\u201318.","journal-title":"Expert Opin Ther Pat"},{"key":"3327_CR8","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s40259-021-00499-2","volume":"35","author":"M Parravano","year":"2021","unstructured":"Parravano M, Costanzo E, Scondotto G, Trifir\u00f2 G, Virgili G. Anti-VEGF and other novel therapies for neovascular age-related macular degeneration: an update. Biodrugs. 2021;35:673\u201392.","journal-title":"Biodrugs"},{"key":"3327_CR9","doi-asserted-by":"publisher","first-page":"e1041","DOI":"10.1111\/aos.14756","volume":"99","author":"XY Zhao","year":"2021","unstructured":"Zhao XY, Meng LH, Liu SZ, Chen YX. Efficacy and safety of different agents, dosages and strategies of anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration: a network meta-analysis of randomized controlled trials. Acta Ophthalmol. 2021;99:e1041\u201350.","journal-title":"Acta Ophthalmol"},{"key":"3327_CR10","doi-asserted-by":"publisher","first-page":"797108","DOI":"10.3389\/fphar.2021.797108","volume":"12","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Gao S, Li X, Huang X, Zhang Y, Chang T, et al. Efficacy and safety of anti-vascular endothelial growth factor monotherapies for neovascular age-related macular degeneration: a mixed treatment comparison. Front Pharmacol. 2021;12:797108.","journal-title":"Front Pharmacol"},{"key":"3327_CR11","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1136\/bjophthalmol-2014-305149","volume":"99","author":"MK Schmid","year":"2015","unstructured":"Schmid MK, Bachmann LM, F\u00e4s L, Kessels AG, Job OM, Thiel MA. Efficacy and adverse events of aflibercept, ranibizumab and bevacizumab in age-related macular degeneration: a trade-off analysis. Br J Ophthalmol. 2015;99:141\u20136.","journal-title":"Br J Ophthalmol"},{"key":"3327_CR12","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162:777\u201384.","journal-title":"Ann Intern Med"},{"key":"3327_CR13","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"J Higgins","year":"2011","unstructured":"Higgins J, Altman D, G\u00f8tzsche P, J\u00fcni P, Moher D, Oxman A, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.","journal-title":"BMJ"},{"key":"3327_CR14","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s12325-020-01236-x","volume":"37","author":"M Ohji","year":"2020","unstructured":"Ohji M, Takahashi K, Okada AA, Kobayashi M, Matsuda Y, Terano Y, et al. Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-week findings from ALTAIR. Adv Ther. 2020;37:1173\u201387.","journal-title":"Adv Ther"},{"key":"3327_CR15","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ophtha.2008.10.018","volume":"116","author":"DM Brown","year":"2009","unstructured":"Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology. 2009;116:57\u201365.","journal-title":"Ophthalmology"},{"key":"3327_CR16","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.ophtha.2023.02.024","volume":"130","author":"C Regillo","year":"2023","unstructured":"Regillo C, Berger B, Brooks L, Clark WL, Mittra R, Wykoff CC, et al. Archway Phase 3 trial of the port delivery system with ranibizumab for neovascular age-related macular degeneration 2-year results. Ophthalmology. 2023;130:735\u201347.","journal-title":"Ophthalmology"},{"key":"3327_CR17","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1001\/jamaophthalmol.2019.5540","volume":"138","author":"PJ Kertes","year":"2020","unstructured":"Kertes PJ, Galic IJ, Greve M, Williams G, Baker J, Lahaie M, et al. Efficacy of a treat-and-extend regimen with ranibizumab in patients with neovascular age-related macular disease. JAMA Ophthalmol. 2020;138:244\u201350.","journal-title":"JAMA Ophthalmol"},{"key":"3327_CR18","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","volume":"119","author":"DF Martin","year":"2012","unstructured":"Martin DF, Maguire MG, Fine SL, Ying G, Jaffe GJ, Grunwald JE, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration. Ophthalmology. 2012;119:1388\u201398.","journal-title":"Ophthalmology"},{"key":"3327_CR19","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/j.ophtha.2020.11.017","volume":"128","author":"RN Khurana","year":"2021","unstructured":"Khurana RN, Kunimoto D, Yoon YH, Wykoff CC, Chang A, Maturi RK, et al. Two-year results of the phase 3 randomized controlled study of abicipar in neovascular age-related macular degeneration. Ophthalmology. 2021;128:1027\u201338.","journal-title":"Ophthalmology"},{"key":"3327_CR20","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.ajo.2007.12.029","volume":"145","author":"AN Antoszyk","year":"2008","unstructured":"Antoszyk AN, Tuomi L, Chung CY, Singh A. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. Am J Ophthalmol. 2008;145:862\u201374.","journal-title":"Am J Ophthalmol"},{"key":"3327_CR21","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.ophtha.2012.10.014","volume":"120","author":"BG Busbee","year":"2013","unstructured":"Busbee BG, Ho AC, Brown DM, Heier JS, Su\u00f1er IJ, Li Z, et al. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2013;120:1046\u201356.","journal-title":"Ophthalmology"},{"key":"3327_CR22","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1016\/j.ophtha.2014.05.009","volume":"121","author":"AC Ho","year":"2014","unstructured":"Ho AC, Busbee BG, Regillo CD, Wieland MR, Van Everen SA, Li Z, et al. Twenty-four-month efficacy and Safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2014;121:2181\u201392.","journal-title":"Ophthalmology"},{"key":"3327_CR23","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ophtha.2020.06.028","volume":"128","author":"PU Dugel","year":"2021","unstructured":"Dugel PU, Singh RP, Koh A, Ogura Y, Weissgerber G, Gedif K, et al. HAWK and HARRIER: 96-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2021;128:89\u201399.","journal-title":"Ophthalmology"},{"key":"3327_CR24","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ophtha.2015.09.018","volume":"123","author":"K Berg","year":"2016","unstructured":"Berg K, Hadzalic E, Gjertsen I, Forsaa V, Berger LH, Kinge B, et al. Ranibizumab or bevacizumab for neovascular age-related macular degeneration according to the lucentis compared to avastin study treat-and-extend protocol. Ophthalmology. 2016;123:51\u20139.","journal-title":"Ophthalmology"},{"key":"3327_CR25","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419\u201331.","journal-title":"N Engl J Med"},{"key":"3327_CR26","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.ophtha.2019.08.023","volume":"127","author":"MC Gillies","year":"2020","unstructured":"Gillies MC, Hunyor AP, Arnold JJ, Guymer RH, Wolf S, Pecheur FL, et al. Macular atrophy in neovascular age-related macular degeneration: a randomized clinical trial comparing ranibizumab and aflibercept (RIVAL Study). Ophthalmology. 2020;127:198\u2013210.","journal-title":"Ophthalmology"},{"key":"3327_CR27","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.ophtha.2006.02.027","volume":"113","author":"DJ D\u2019Amico","year":"2006","unstructured":"D\u2019Amico DJ, Grp VCT. Pegaptanib sodium for neovascular age-related macular degeneration. Ophthalmology. 2006;113:992\u20131001.","journal-title":"Ophthalmology"},{"key":"3327_CR28","first-page":"1501","volume":"113","author":"U Chakravarthy","year":"2006","unstructured":"VEGF Inhibition Study In Ocular Neovascularization Clinical Trial Group, Chakravarthy U, Adamis AP, Cunningham ET Jr, Goldbaum M, Guyer DR, Katz B, et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology. 2006;113:1501\u20138.","journal-title":"Ophthalmology."},{"key":"3327_CR29","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ophtha.2013.08.011","volume":"121","author":"U Schmidt-Erfurth","year":"2014","unstructured":"Schmidt-Erfurth U, Kaiser PK, Korobelnik J, Brown DM, Chong V, Nguyen QD, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration. Ophthalmology. 2014;121:193\u2013201.","journal-title":"Ophthalmology"},{"key":"3327_CR30","doi-asserted-by":"crossref","unstructured":"Khanani AM, Kotecha A, Chang A, Chen S, Chen Y, Guymer R, et al. TENAYA and LUCERNE: two-year results from the phase 3 neovascular age-related macular degeneration trials of faricimab with treat-and-extend dosing in year 2. Ophthalmology. 2024;131:1\u201313.","DOI":"10.1016\/j.ophtha.2024.02.014"},{"key":"3327_CR31","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.3390\/biom12111629","volume":"12","author":"RH ElSheikh","year":"2022","unstructured":"ElSheikh RH, Chauhan MZ, Sallam AB. Current and novel therapeutic approaches for treatment of neovascular age-related macular degeneration. Biomolecules. 2022;12:1629.","journal-title":"Biomolecules"},{"key":"3327_CR32","doi-asserted-by":"publisher","first-page":"135","DOI":"10.2174\/1871530315666150316121956","volume":"15","author":"M Shibuya","year":"2015","unstructured":"Shibuya M. VEGF-VEGFR system as a target for suppressing inflammation and other diseases. Endocr Metab Immune Disord Drug Targets. 2015;15:135\u201344.","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"3327_CR33","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12974-019-1419-2","volume":"16","author":"C Balser","year":"2019","unstructured":"Balser C, Wolf A, Herb M, Langmann T. Co-inhibition of PGF and VEGF blocks their expression in mononuclear phagocytes and limits neovascularization and leakage in the murine retina. J Neuroinflamm. 2019;16:26.","journal-title":"J Neuroinflamm"},{"key":"3327_CR34","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.ophtha.2019.09.021","volume":"127","author":"JS Heier","year":"2020","unstructured":"Heier JS, Wykoff CC, Waheed NK, Kitchens JW, Patel SS, Vitti R, et al. Intravitreal combined aflibercept + anti\u2013platelet-derived growth factor receptor \u03b2 for neovascular age-related macular degeneration. Ophthalmology. 2020;127:211\u201320.","journal-title":"Ophthalmology"},{"key":"3327_CR35","doi-asserted-by":"publisher","first-page":"e820","DOI":"10.1111\/aos.14399","volume":"98","author":"MI L\u00f3pez G\u00e1lvez","year":"2020","unstructured":"L\u00f3pez G\u00e1lvez MI, Arias Barquet L, Figueroa MS, Garc\u00eda Layana A, Ruiz Moreno JM. Bimonthly, treat\u2010and\u2010extend and as-needed ranibizumab in na\u00efve neovascular age-related macular degeneration patients: 12-month outcomes of a randomized study. Acta Ophthalmol. 2020;98:e820\u20139.","journal-title":"Acta Ophthalmol"},{"key":"3327_CR36","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.2147\/DDDT.S97653","volume":"10","author":"X Sun","year":"2016","unstructured":"Sun X, Yang S, Zhao J. Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review. Drug Des Devel Ther. 2016;10:1857\u201367.","journal-title":"Drug Des Devel Ther"},{"key":"3327_CR37","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1016\/j.ophtha.2016.03.045","volume":"123","author":"MG Maguire","year":"2016","unstructured":"Maguire MG, Martin DF, Ying G, Jaffe GJ, Daniel E, Grunwald JE, et al. Five-year outcomes with anti\u2013vascular endothelial growth factor treatment of neovascular age-related macular degeneration. Ophthalmology. 2016;123:1751\u201361.","journal-title":"Ophthalmology"},{"key":"3327_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.852519","volume":"9","author":"H Jia","year":"2022","unstructured":"Jia H, Lu B, Yuan Y, Yuan F, Li L, Song Y, et al. A randomized, controlled trial of treat-and-extend vs. pro re nata regimen for neovascular age-related macular degeneration. Front Med. 2022;9:852519.","journal-title":"Front Med"},{"key":"3327_CR39","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1136\/bjophthalmol-2021-319637","volume":"107","author":"NM Bressler","year":"2023","unstructured":"Bressler NM, Veith M, Hamouz J, Ernest J, Zalewski D, Studni\u010dka J, et al. Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomes. Br J Ophthalmol. 2023;107:384\u201391.","journal-title":"Br J Ophthalmol"},{"key":"3327_CR40","doi-asserted-by":"publisher","first-page":"e275611","DOI":"10.1371\/journal.pone.0275611","volume":"17","author":"CK Yoon","year":"2022","unstructured":"Yoon CK, Oh J, Bae K, Park UC, Yu K, Yu HG. Efficacy and safety of a new ranibizumab biosimilar CKD-701 using a pro re nata treatment regimen in neovascular age-related macular degeneration: A phase 3 randomized clinical trial. PLoS ONE. 2022;17:e275611.","journal-title":"PLoS ONE"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-024-03327-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-024-03327-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-024-03327-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T11:03:12Z","timestamp":1733396592000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-024-03327-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,11]]},"references-count":40,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["3327"],"URL":"https:\/\/doi.org\/10.1038\/s41433-024-03327-3","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,11]]},"assertion":[{"value":"12 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}